SuperworthJazz Pharmaceuticals EPS JAZZ
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $14.62
- Latest quarter, Q2 FY26
- $2.78
- Fiscal year 2025
- −$5.85
- −167% on the year before
Jazz Pharmaceuticals' earnings per share was $14.62 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $2.78.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$5.85 | −167% |
| FY2024 | $8.79 | +45% |
| FY2023 | $6.05 | n/a |
| FY2022 | −$3.55 | n/a |
| FY2021 | −$5.45 | −229% |
| FY2020 | $4.21 | −54% |
| FY2019 | $9.10 | +25% |
| FY2018 | $7.30 | −8% |
| FY2017 | $7.95 | +24% |
| FY2016 | $6.42 | +23% |
| FY2015 | $5.23 | +530% |
| FY2014 | $0.83 | −76% |
| FY2013 | $3.53 | −26% |
| FY2012 | $4.76 | +78% |
| FY2011 | $2.67 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $2.78 | n/a | $14.62 | |
| Q1 FY26 | $4.43 | n/a | $0.10 | |
| Q4 FY25 | $3.33 | +7% | −$5.85 | |
| Q3 FY25 | $4.08 | +19% | −$6.07 | |
| Q2 FY25 | −$11.74 | −571% | −$6.73 | |
| Q1 FY25 | −$1.52 | n/a | $7.50 | |
| Q4 FY24 | $3.11 | +130% | $8.79 | |
| Q3 FY24 | $3.42 | +60% | $7.03 | |
| Q2 FY24 | $2.49 | +64% | $5.75 | |
| Q1 FY24 | −$0.23 | −122% | $4.78 | |
| Q4 FY23 | $1.35 | n/a | $6.05 | |
| Q3 FY23 | $2.14 | n/a | $0.88 |
Against its peers
Companies in Drug Manufacturers - General nearest Jazz Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| JAZZJazz Pharmaceuticals | $14.62 | |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| BIIBBiogen | $5.65 | −46% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| Peer median | $1.00 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Jazz Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.